EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...

The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients with early-stage non-small cell lung cancer (NSCLC). Published in the journal ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Please provide your email address to receive an email when new articles are posted on . Guidelines for the management of early-stage non-small cell lung cancer were last published in 2013. The new ...

Accelerated approval expands zongertinib from post–systemic therapy (Aug 2025) into the untreated setting for HER2 (ERBB2) TKI-domain activating mutation–positive non-squamous NSCLC. A 76% objective ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...